
BCC BOSTON CONSULTING GROUP

Journey of change towards Value-Based Procurement


Goetz Gerecke - Managing Director and Senior Partner

1 DECEMBER 2020

Value based procurement journey to date



Where are we on the journey of change?



Commitment

Health systems are committed to change and adopt VBP as core principle Importance

Health care stakeholders acknowledge importance of VBP

Enthusiasm

Providers and medtech are enthusiastic to adopt VBP

Readiness

Providers and medtech have the capabilities and resources to implement VBP

Adoption

Providers and medtech are implementing VBP

Medium

High

Impact

Those who have adopted VBP generate value


Low



Assessment:



Health systems and GPOs are starting to commit to VBP



Note: Selection of examples only

Source: Medtech Europe, industry and procurer interviews, CoP events, desk research, BCG; Medtech Europe; BCG analysis

Importance/enthusiasm/readiness




Pulse check #1 - Let's jointly review the status of VBP adoption in your organizations



2

Take your smart phone and connect to WWW.MENTI.COM


Select your organization type and enter the related code



Jointly review the results



Please keep the app open for a final question later in the presentation



Importance/enthusiasm/readiness

Enthusiasm for VBP²



Recap: Results of 2019 survey (I)

Importance of VBP¹

Substantial change Procurer **79**% 37% High required for procurers (n = ~35)15% 40% Medium + 6% 23% Low MedTech High **68**% 77% (n = -65)19% Medium 23% 10% 3% Low

1. How important do you see VBP and its rollout for your organization's success today? 2. What is the level of enthusiasm for VBP within your organization? Source: VBP online survey; BCG analysis


Importance/enthusiasm/readiness




Recap: Results of 2019 survey (II)

VBP readiness - internal view¹

VBP readiness - external view²






39%

1. How do you rate your organization's readiness for VBP today? 2. How do you rate medtech suppliers/procurers (respectively) readiness for VBP? Source: VBP online survey; BCG analysis




Adoption: Making sense of the TED EU tender database

	andare alastropie dail		About TE	D Help Legal notice Cookies Contact English (en)	
	pplement to the Official Journal of the EU	У		Search TED for public tenders Advanced search / Expert search	
ROPA > TED home > Advanced D TED SIMAP TED eNotice		BC	BD	BF	
		50	00		
Check out our COVID-19 dedicated page for tenders related to medical equipment needs.		М	60	Implementation and product support	40
		M	60	Qualität und Funktionalität	40
		М	60	okres gwarancjiparametry techniczne	5;0035;00
Manage saved search Switch to expert mode		М	60	Czas realizacji reklamacji sprzÄtuSzkoleniaTermin ważnoÅci dostarczonego sprzÄtu	102010
		М	60	JakoÅÄ - parametry techniczneWarunki gwarancji	2020
		М		Cena bruttoCzas realizcji zamówienia	6040
		М	60	Termin dostawyTermin przydatnoÅci do użyciaTermin pÅatnoÅci	201010
Search scope	O Current OJ S issue ? Active notices ? O All i	М	60	Comodidad de uso para profesional y pacienteFacilidad de manejo para la implantaciÃ ³ n: Na 101010	
		м		CenaTermin pÅatnoÅci	6040
		М	60	ÐаÑÐμÑÑво	40
^ Text	Find results containing	L			
- Text	-	М		Cena pÅÃ-stroje/Å ⁻ (bez DPH)ServisnÃ- nÃį klady za celkový poÄet pÅÃ-strojÅ ⁻ (bez DPH)-	T 602020
	?	М	90	Rok isporuke robe	10 %
		L			
∧ Business opportunities	More option	L			
		М	95	Capped PricingPriority Supplier ProgrammeQuality	32Pass/Fail
	Planning Competition Result ?	М	60	Parametry techniczne	40
		М	60	gwarancja	40
^ Subject matter of the	Common procurement vocabulary (CPV) Type of co				
contract		М	40	Criterios objetivosCriterios subjetivos	4020
		М		VýÅje nabÃ-dkové ceny	100



50%


Leading countries already with high MEAT penetration and much lower price weight



1. Most Economically Advantageous Tenders 2. Ireland, France, Belgium, Netherlands, Spain for MEAT, plus NO and IT for weight of price Source: TED database; BCG analysis



MEAT penetration and price weight highly correlated with exception of Norway and Italy



1. Assuming 100% price weight in L (lowest price) tenders and indicated price weight for M (MEAT) tenders (based on sample of M tenders in which price weight was indicated) Source: TED database; BCG analysis




Increasing number of tenders with collaborative procedures but still only low share

Contract notices with collaborative procedures (as % of total number of contract notices)



<u>But:</u> Share of tenders with low price weight (<30%) growing substantially in Western Europe

Share of MEAT¹ tenders with price criteria weight less than 30% in Western Europe



Adoption



Pulse check #2 - Let's now review the main obstacles to implement VBP in your organization



Take your smart phone again



2

Select the 3 main challenges to VBP implementation in your organization





Let's review the results



In case you got locked out:



Connect to WWW.MENTI.COM



Select your organization type and enter the related code:



Medtech

Provider / procurer

Ð




Recap: Main challenges for procurers from 2019 survey

Procurer self-perception

(Top 3 obstacles¹; n = -35)







1. Within your organization, what are major obstacles and challenges regarding the implementation of VBP? Please rank the top three from your perspective. 2. On the hospital/procurer side, what are major obstacles and challenges regarding the implementation of VBP? Please rank the top three from your perspective' Source: VBP online survey; BCG analysis




Recap: Main challenges for medtech from 2019 survey

Medtech self-perception

(Top 3 obstacles¹; n = -65)

Procurer view on Medtech

(Top 3 obstacles²; n = -35)




1. Within your organization, what are major obstacles and challenges regarding the implementation of VBP? Please rank the top three from your perspective. 2. What are major obstacles and challenges on the medical technology industry's side? Please rank the top three from your perspective 5. Other such as 'Lack of demand from procurers' Source: VBP online survey; BCG analysis



Early adopters are reaping substantial benefits

Broad adoption of VBP framework



Criteria applied at High frequency Medium frequency Low frequency

2. Leading medtech company

1. Ferran Rodrígues Omedes, head of clinical and biomedical engineering at the University Hospital Clinic Barcelona Source: VBP belief audits: VBP online survey: VBP belief audit interviews: VBP case study deep dives: BCG analysis

Benefiting providers and medtech



We looked back at past tenders & presume that a large amount would have had a different result¹



We won 70% of VBP pilot tenders with a higher price realization. That's virtually double our market share²

The time to act is now!



The status quo is not sustainable



A win-win for all stakeholders



VBP is not easy, but ready to move at scale

"Never let a good crisis go to waste"

Winston Churchill

Any questions?



Please reach out for further discussion



Goetz Gerecke, Senior Partner & Managing Director, gerecke.goetz@bcg.com



Hans Bax, Senior Advisor VBP, hans.bax@meat-procurement.eu

Disclaimer

The services and materials provided by Boston Consulting Group (BCG) are subject to BCG's Standard Terms (a copy of which is available upon request) or such other agreement as may have been previously executed by BCG. BCG does not provide legal, accounting, or tax advice. The Client is responsible for obtaining independent advice concerning these matters. This advice may affect the guidance given by BCG. Further, BCG has made no undertaking to update these materials after the date hereof, notwithstanding that such information may become outdated or inaccurate.

The materials contained in this presentation are designed for the sole use by the board of directors or senior management of the Client and solely for the limited purposes described in the presentation. The materials shall not be copied or given to any person or entity other than the Client ("Third Party") without the prior written consent of BCG. These materials serve only as the focus for discussion; they are incomplete without the accompanying oral commentary and may not be relied on as a stand-alone document. Further, Third Parties may not, and it is unreasonable for any Third Party to, rely on these materials for any purpose whatsoever. To the fullest extent permitted by law (and except to the extent otherwise agreed in a signed writing by BCG), BCG shall have no liability whatsoever to any Third Party, and any Third Party hereby waives any rights and claims it may have at any time against BCG with regard to the services, this presentation, or other materials, including the accuracy or completeness thereof. Receipt and review of this document shall be deemed agreement with and consideration for the foregoing.

BCG does not provide fairness opinions or valuations of market transactions, and these materials should not be relied on or construed as such. Further, the financial evaluations, projected market and financial information, and conclusions contained in these materials are based upon standard valuation methodologies, are not definitive forecasts, and are not guaranteed by BCG. BCG has used public and/or confidential data and assumptions provided to BCG by the Client. BCG has not independently verified the data and assumptions used in these analyses. Changes in the underlying data or operating assumptions will clearly impact the analyses and conclusions.



bcg.com